Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
Primer İnsomni ve Nörodejeneratif Hastalıklarda Ketiapinin Uyku Yapısı ve Devamlılığı Üzerine Etkisinin Polisomnografi Verileri ile Retrospektif Değerlendirilmesi. (Turkish)
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
- معلومة اضافية
- Alternate Title:
Retrospective Evaluation of the Effects of Quetiapine on Sleep Structure and Continuity in Primary Insomnia and Neurodegenerative Diseases with Polysomnographic Data. (English)
- نبذة مختصرة :
Objective: The study retrospectively evaluated the effects of quetiapine on sleep in primary insomnia and neurodegenerative diseases using polysomnographic data. Materials and Methods: Between January 1, 2010, and June 1, 2023, the records of 49 patients who were followed up in the sleep outpatient clinic of the neurology department of our hospital and who underwent polysomnography examination were retrospectively reviewed. Patients aged between 18 and 65 years with primary insomnia and neurodegenerative diseases were included in the study. Results: The mean age of 49 patients (26 females and 23 males) were 56.67 years. The mean quetiapine dose was 59.37. Sleep latency, stage 1 (N1) duration, stage 2 (N2) duration, mean and minimum SO2 and apnea-hypopnea index were similar. Total sleep duration, stage 3 (N3) duration and rapid eye movement (REM) sleep duration were higher in neurodegenerative patients. N3 duration was shorter in patients with primary insomnia on quetiapine. Sleep duration and REM duration were longer in the neurodegenerative group and sleep latency was longer in primary insomnia in quetiapine users. Among quetiapine users, the N2 sleep percentage was higher and the nonREM 3 sleep percentage was lower in primary insomnia, whereas there was no difference in sleep percentages in neurodegenerative patients. Conclusion: Quetiapine is an atypical antipsychotic agent. It shortens sleep latency and decreases the percentage of REM sleep and wake time. It increases total sleep time, sleep efficiency, and N2 sleep. In this study, in primary insomnia patients using quetiapine, N3 sleep duration was shorter and sleep percentage was lower, whereas N2 sleep percentage was longer. There has been no placebo-controlled study of any antipsychotic drug for treating insomnia. [ABSTRACT FROM AUTHOR]
- نبذة مختصرة :
Amaç: Bu çalışmada primer insomni ve nörodejeneratif hastalıklarda ketiapinin uyku üzerine etkilerinin polisomnografi verileri ile retrospektif değerlendirilmesi amaçlanmıştır. Gereç ve Yöntem: 1 Ocak 2010-1 Haziran 2023 tarihleri arasında hastanemiz nöroloji anabilim dalı uyku polikliniğinde takip edilen, polisomnografi tetkiki yapılmış 49 hastanın kayıtları retrospektif incelendi. Çalışmaya 18-65 yaş arasında primer insomni ve nörodejeneratif hastalık tanısı alan hastalar dahil edildi. Bulgular: Yirmi altı kadın, 23 erkek toplam 49 hastanın ortalama yaşı 56,67 idi. Ketiapin dozu ortalaması 59,37 idi. Uyku latansı, evre 1 (N1) süresi, evre 2 (N2) süresi, ortalama ve minimum SO2 ve apne-hipopne indeksi benzerdi. Toplam uyku süresi, evre 3 (N3) süresi ve hızlı göz hareketi/rapid eye movement (REM) uyku süreleri nörodejeneratif hastalarda daha fazlaydı. Ketiapin kullanan primer insomnili olgularda non-REM 3 süresi daha kısaydı. Ketiapin kullananlarda uyku süresi ve REM süresi nörodejeneratif grupta, uyku latansı ise primer insomnide daha uzundu. Ketiapin kullanan hastalardan primer insomnide N2 uyku yüzdesi daha yüksek, N3 uyku yüzdesi ise daha düşük iken nörodejeneratif hastalarda uyku yüzdelerinde fark yoktu. Sonuç: Ketiapin, bir atipik antipsikotik ajandır. Uyku latansını kısaltır, REM uyku yüzdesini ve uyanıklık süresini azaltır. Toplam uyku süresini, uyku etkinliğini, N2 uykusunu ise artırır. Bu çalışmada ketiapin kullanan primer insomni olgularında N3 süresi daha kısa ve uyku yüzdesi daha düşük, N2 uyku yüzdesi ise daha uzundu. İnsomni tedavisinde herhangi bir antipsikotik ilacın plasebo kontrollü çalışması yoktur. [ABSTRACT FROM AUTHOR]
- نبذة مختصرة :
Copyright of Journal of Turkish Sleep Medicine is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
No Comments.